Autologous bone marrow transfusion to treat the tibia diaphyseal nonunions

Background: Bone marrow stem cells with their plasticity can be used to replace and repair the other damaged organs and tissues, so they can also be used to obtain bone healing of nonunions. Objective: to evaluate the results of percutaneous autologous bone marrow grafting to treat the tibia diaphyseal nonunions. Subjects and methods: 12 patients with noninfected nonunion of the tibia were diagnosed and treated in Viet Duc Hospital. About 250mL of marrow was aspirated, then separated and concentrated by density gradient centrifugation. The final mononuclear cell mass containing stem cells and progenitors was washed in 30ml of 0.9% NaCL and then injected into the damaged sites. Patients were evaluated by clinical and X-rays examinations with at least 6 months follow-up. Results: None of the patients had post - op complications. Bone union was obtained in eleven of the twelve patients (91,7%) at an average of 15,3 weeks (range, 9 - 30 weeks), the bone marrow grafts used for these patients who had bone union contained a mean of 5,65 \xb1 3,74 x 106 (0,95 - 11,73 x 106) CD34(+) stem cells in total. Conclusions: Percutaneous autologous bone - marrow grafting is a minimally invasive alternative and a simple, effective, safe method for the treatment of the tibia diaphyseal nonunions with the comparative bone healing rate. \r\n', u'\r\n', u'

Changes of the coagulation factors II,V,VII, and X in patients with active chronic hepatitis and ascitic cirrhosis due to hepatitis B

30 patients with the active chronic hepatitis B and 30 patients with the ascitic cirrhosis due to hepatitis B from the Army Central Hospital 108 and the National Institute of Clinical Medicine and tropical diseases participated to a study. The results have shown that the coagulation factors II, V, VII, and X in patients with the active chronic hepatitis B were moderately reduced during the exacerbation of the disease and gradually recovered to a normal level or almost normal level during the stable disease. While these factors in the patients with ascitic cirrhosis were severely, unreversible reduced through the progress of disease. During the exacerbation of the diseases. The extend of reduction of the above coagulation factors in patients of the ascitic cirrhosis was more severe than these in patients with the active chronic hepatitis B.